Data On Novartis’ Heart Failure Drug LCZ696 Fans Blockbuster Talk
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis ended a late-stage clinical trial testing LCZ696 early after results showed patients treated with the first-in-class pill lived longer without being hospitalized than a group receiving standard care with an ACE inhibitor.